Please login to bookmark Close

Pfizer, maker of the blockbuster rheumatoid arthritis biologic Enbrel, has taken generic drug maker Sandoz to court for information on its Enbrel biosimilar, after winning a bid for preliminary discovery against Samsung Biopis to pursue a possible infringement case over the same drug.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au